Pavilion Publishing and Media Ltd
Blue Sky Offices Shoreham, 25 Cecil Pashley Way, Shoreham-by-Sea, West Sussex, BN43 5FF, UNITED KINGDOM
The first inhaled corticosteroid/long acting beta2-agonist (ICS/LABA) combination to provide continuous 24-hour efficacy for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in a practical once-daily dose has been launched.Relvar is a combination of the inhaled corticosteroid (ICS), fluticasone furoate and the long-acting beta2-agonist, vilanterol and is the first ICS/LABA to launch with both an asthma and COPD indication at the same time. Two strengths have been approved for the treatment of asthma (92/22mcg and 184/22mcg) and one strength has been approved for COPD (92/22mcg). All strengths will be administered once-daily using the Ellipta, a new dry powder inhaler.